Next, we treated HepG2 cells with BCNU, a chemical inhibitor of GR, the enzyme converting GSSG back into GSH
The ATTAIN-MAINTAIN trial asked a particularly interesting question: can orforglipron maintain weight loss initially achieved with injectable tirzepatide or semaglutide
doi: 10.3389/fendo.2026.1833904 Received 18 March 2026 Revised 31 May 2026 Accepted 11 June 2026 Published 03 July 2026 Corrected 20 July 2026 Volume 17 - 2026 Edited by Takefumi Kimura, Shinshu University, Japan Reviewed by Venkata Madhavi Latha Telagarapu, University of Miami, United States Suzanne Riskin, Nova Southeastern University, United States Updates Copyright 2026 Omarion, Ayasa, Omarion, Jayouse and Ayesh
Castellani, M
The 3-point MACE event rates (including MI, ischemic stroke, and CV-related death) did not differ across weight loss categories ( X 2 = 1.31